Obstetrics and gynecology · 2019 · Clinical trial · PMID 31599840
Explore the library
Insufficient evidenceBremelanotide; melanocortin receptor agonist
PT-141 / Bremelanotide
PT-141 is a research name for bremelanotide, a melanocortin-receptor agonist. The finished product Vyleesi has a specific FDA-approved indication, not a general enhancement indication.
Also indexed as: Bremelanotide · Vyleesi
A clear starting point
PT-141 is a research name for bremelanotide, a melanocortin-receptor agonist. The finished product Vyleesi has a specific FDA-approved indication, not a general enhancement indication.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
Melanocortin signaling
PT-141 is a research name for bremelanotide, a melanocortin-receptor agonist. The finished product Vyleesi has a specific FDA-approved indication, not a general enhancement indication.
- Targets & processes
- Melanocortin signaling
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
Sexual-desire outcomes within a narrowly defined clinical indication.
What this does not establish
Phase 3 findings apply to premenopausal women with acquired generalized HSDD, not general sexual-performance enhancement or research-grade PT-141 products.
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
The approved product is contraindicated in uncontrolled hypertension or known cardiovascular disease. Risks include transient blood-pressure increases, nausea and focal hyperpigmentation.
Contraindications & cautions
Not an exhaustive contraindication review. The approved product is contraindicated in uncontrolled hypertension or known cardiovascular disease. Risks include transient blood-pressure increases, nausea and focal hyperpigmentation.
Medication & supplement interactions
Interaction information is incomplete. The approved product is contraindicated in uncontrolled hypertension or known cardiovascular disease. Risks include transient blood-pressure increases, nausea and focal hyperpigmentation.
Regulatory status · United States
FDA-approved product · narrow indication. Vyleesi (bremelanotide) is approved for premenopausal women with acquired generalized HSDD under label criteria, not sexual-performance enhancement.
Read the official sourceThis is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.